The U.S. Food and Drug Administration is slated to decide on approving Capricor’s Deramiocel for the treatment of Duchenne muscular dystrophy by November 22.
The U.S. Food and Drug Administration is slated to decide on approving Capricor’s Deramiocel for the treatment of Duchenne muscular dystrophy by November 22.
Estimated approval odds are 62% for Capricor’s therapy, 85% for Savara’s drug facing the same Sunday target date, and 79% for Sanofi’s drug awaiting a Nov.25 decision.
Greenwich said two research abstracts related to its experimental breast cancer drug were accepted for the San Antonio Breast Cancer Symposium, scheduled for December 8 to 11.